Table 4 Scenario analyses
Total cost | Total QALY | ICER | |||||
|---|---|---|---|---|---|---|---|
As-needed budesonide-formoterol | Low-dose maintenance ICS + as-needed SABA | As-needed budesonide-formoterol | Low-dose maintenance ICS + as-needed SABA | Incremental cost | Incremental QALY | Dominant strategy | |
Scenario 1: discount rate 0% | $48,996 | $62,385 | 34.579 | 34.576 | − $13,388 | 0.003 | As-needed budesonide-formoterol |
Scenario 2: discount rate 3% | $28,346 | $35,890 | 20.136 | 20.135 | − $7544 | 0.001 | As-needed budesonide-formoterol |
Scenario 3: time horizon 2y | $2417 | $3078 | 1.723 | 1.723 | − $662 | 0.000 | As-needed budesonide-formoterol |
Scenario 4: time horizon 10y | $11,338 | $14,398 | 8.093 | 8.093 | − $3061 | 0.000 | As-needed budesonide-formoterol |
Scenario 5: societal perspective | $37,387 | $47,269 | 25.960 | 25.958 | − $9882 | 0.002 | As-needed budesonide-formoterol |
Scenario 6: budesonide as low-dose maintenance ICS | $36,546 | $50,976 | 26.030 | 26.028 | − $14,431 | 0.002 | As-needed budesonide-formoterol |
Scenario 7: ICS utilization adjusted to 62.8% (fixed) | $36,700 | $43,606 | 25.177 | 25.175 | − $6906 | 0.002 | As-needed budesonide-formoterol |
Scenario 8: removal of AEs from the analysis | $8449 | $12,002 | 25.369 | 25.367 | − $3552 | 0.002 | As-needed budesonide-formoterol |